The first three months after starting an antipsychotic medicine are a critical window for a patient's physical health, according to a study led by University College London researchers and published in The Lancet Psychiatry.

The observational study, funded by the National Institute for Health and Care Research, analysed NHS GP records for nearly 97,000 adults aged 18 to 59 in England with severe mental illness who started treatment with olanzapine, quetiapine, risperidone or aripiprazole between 2000 and 2023, comparing the two years before treatment with the two years after. In the first 90 days, glycated haemoglobin (HbA1c) — a measure of average blood glucose — rose around 14 times faster, and weight around nine times faster, than before treatment began.

Olanzapine was associated with the largest early changes of the four medicines, with HbA1c rising around 50 times faster and weight around 10 times faster in the first 90 days. Among patients who had prediabetes when treatment began, 19 per cent developed type 2 diabetes within two years, compared with 3 per cent of those whose blood glucose was initially normal, and women experienced greater early increases in HbA1c than men.

The researchers stress that changes in blood glucose and weight did not always occur together — so monitoring weight alone can miss metabolic changes that are already under way. “The first 90 days after starting treatment are a key period when changes linked to diabetes and weight gain can begin,” said first author Dr. Juan Carlos Bazo-Alvarez of UCL Epidemiology and Health.

The practical message for clinics is timing: blood-glucose and weight checks belong in the first weeks of treatment, not at an annual review, when the fastest changes may already have happened.